Labcorp Adopts Molecular Loop SARS-CoV-2 Research Sequencing Panel for Large-Scale Viral Surveillance
06/22/2021 - 08:28 AM
NEWTON, Mass. , June 22, 2021 /PRNewswire/ -- Molecular Loop Biosciences, Inc. , a company redefining the simplicity of targeted sequencing, announced today that its SARS-CoV-2 Research Sequencing Panel has been deployed by Labcorp (NYSE: LH), a leading global life sciences company, to help sequence thousands of complete coronavirus genomes each week from positive patient samples. This sequencing is being performed as part of a U.S. Centers for Disease Control and Prevention (CDC) effort to identify and track the spread of SARS-CoV-2 variants throughout the country.
"While next-generation DNA sequencing has become the preferred solution for coronavirus variant identification and monitoring, the sample preparation method used greatly impacts both its scalability and the quality of the data that are generated. We are thrilled that our effort to adapt our technology to targeted viral RNA sequencing at scale has allowed us to play a role in this critical effort to combat the spread of coronavirus," said Greg Porreca , Co-Founder and Chief Executive Officer of Molecular Loop.
The Molecular Loop SARS-CoV-2 Research Sequencing Panel converts extracted RNA samples into sequencer-ready libraries in four simple steps, making it easy to implement and scale for Illumina or PacBio sequencing. Redundant probe tiling technology allows for the detection of emerging variants while alleviating the concern of amplicon or allele dropouts that can occur in amplicon-based workflows.
"We are confident that the simplicity of our workflow, coupled with high genome completion rates across a wide range of Ct values, will maximize the yield of this critical information from patient samples," said Pat Saunders , Molecular Loop's Head of Technology Implementation.
About Molecular Loop Molecular Loop provides customized, targeted next-generation sequencing solutions using its novel molecular inversion probe technology, delivering industry-leading workflow simplicity without sacrificing data quality. The company is leveraging its technology and deep genomic expertise to accelerate innovations in life sciences and make advancements in personalized healthcare. The team is passionate about making it easier than ever for labs to harness the power of genomic technology and make genetic testing more broadly accessible.
View original content to download multimedia:http://www.prnewswire.com/news-releases/labcorp-adopts-molecular-loop-sars-cov-2-research-sequencing-panel-for-large-scale-viral-surveillance-301317246.html
SOURCE Molecular Loop Biosciences, Inc.
Laboratory Corp. Of America Holdings
NYSE:LH
LH Rankings
#1736 Ranked by Stock Gains
LH Stock Data
Industry
Diagnostic Imaging Centers
Sector
Health Care and Social Assistance
Tags
Health Services, Services to the Health Industry, Manufacturing, Dental Laboratories
Country
US
City
Burlington
About LH
recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.